公开(公告)号：US20050154064A1

公开(公告)日：2005-07-14

申请号：US10968561

申请日：2004-10-18

Applicant: Daniele Piomelli ,  Fernando de Fonseca

Inventor： Daniele Piomelli ,  Fernando de Fonseca

IPC: A23L1/30 ,  A61K20060101 ,  A61K31/16 ,  A61K31/164 ,  A61K31/195 ,  A61K31/20

CPC classification number: A61K31/164 ,  A23L33/12 ,  A23V2002/00 ,  A61K31/16 ,  A23V2250/188 ,  A23V2200/332 ,  A23V2250/186 ,  A23V2250/1872 ,  A23V2250/1874

Abstract: Methods, pharmaceutical, dietary supplement, and nutraceutical compositions, and compounds for reducing body weight, modulating body lipid metabolism, and reducing food intake in mammals are provided. The compounds of the invention include fatty acid ethanolamide compounds, homologues and analogs of which the prototype is the endogenous fatty acid ethanolamide, oleoylethanolamide.

Abstract translation: 提供了方法，药物，膳食补充剂和营养保健组合物，以及用于减少体重，调节体内脂质代谢和减少哺乳动物食物摄入的化合物。 本发明的化合物包括脂肪酸乙醇酰胺化合物，其原型是内源性脂肪酸乙醇酰胺的同系物和类似物，油基乙醇酰胺。

公开(公告)号：US20050101542A1

公开(公告)日：2005-05-12

申请号：US10642462

申请日：2003-08-15

Applicant: Daniele Piomelli ,  Fernando de Fonseca ,  Jin Fu ,  Silvana Gaetani

Inventor： Daniele Piomelli ,  Fernando de Fonseca ,  Jin Fu ,  Silvana Gaetani

IPC: A61K31/415 ,  A61K31/70 ,  A61K45/06

CPC classification number: A61K31/415 ,  A61K31/70 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention provides methods and pharmaceutical compositions for administering a PPARα agonist (e.g., OEA-like agonist, OEA-like compound), an OEA-like appetite reducing compound, or a FAAH inhibitor and a CB1 cannabinoid receptor antagonist to a subject in order to reduce the consumption or ingestion of food, ethanol or other appetizing substances as well as in treating appetency disorders related to the excess consumption of food, ethanol, and other appetizing substances. The combination therapy can also be useful for reducing body fat or body weight and modulating lipid metabolism.

Abstract translation: 本发明提供了用于向受试者施用PPARα激动剂（例如，OEA样激动剂，OEA样化合物），类似OEA的食欲降低化合物或FAAH抑制剂和CB1大麻素受体拮抗剂的方法和药物组合物，以便 减少食物，乙醇或其他开胃物质的消耗或摄入，以及治疗与食物，乙醇和其他开胃物质过量消费有关的食欲障碍。 联合治疗也可用于减少体脂肪或体重并调节脂质代谢。